Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 1;179(1):91-93.
doi: 10.1001/jamapediatrics.2024.4449.

Pediatric Exclusivity Revenues for Cancer Drugs

Ameet Sarpatwari  1 , Liam Bendicksen  1 , Douglas S Hawkins  2 , Lia Gore  3 , Florence T Bourgeois  4   5   6
Affiliations

Pediatric Exclusivity Revenues for Cancer Drugs

Ameet Sarpatwari et al. JAMA Pediatr. .

Erratum in

  • Errors in the Results and Table.
    [No authors listed] [No authors listed] JAMA Pediatr. 2025 Jan 1;179(1):106. doi: 10.1001/jamapediatrics.2024.6253. JAMA Pediatr. 2025. PMID: 39760757 Free PMC article. No abstract available.
No abstract available

Plain language summary

This cohort study calculates the cost of pediatric trials and the value of pediatric exclusivity for select cancer drugs.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Mr Bendicksen reported receiving an article contest award from the PhRMA Foundation outside the submitted work. Dr Hawkins reported receiving grants from Seattle Children’s Hospital during the conduct of the study. No other disclosures were reported.

Figures

Figure.
Figure.. Per Exclusivity Cost of Investment for Pediatric Trials vs Pediatric Exclusivity Attributable Revenue
The primary analysis assumed a 10% cost of capital and a 55% market-share erosion rate. The sensitivity analysis for lower return on investment (ROI) assumed a 5% cost of capital and a 70% market-share erosion rate. The sensitivity analysis for higher ROI assumed a 15% cost of capital and a 40% market-share erosion rate.
See this image and copyright information in PMC

References

    1. Bourgeois FT, Kesselheim AS. Promoting pediatric drug research and labeling—outcomes of legislation. N Engl J Med. 2019;381(9):875-881. doi:10.1056/NEJMhle1901265 - DOI - PubMed
    1. Pediatric exclusivity granted. US Food and Drug Administration. January 25, 2024. Accessed July 16, 2024. https://www.fda.gov/drugs/development-resources/pediatric-exclusivity-gr...
    1. Hawkins DS, Gore L. Children’s Oncology Group’s 2023 blueprint for research. Pediatr Blood Cancer. 2023;70(suppl 6):e30569. doi:10.1002/pbc.30569 - DOI - PMC - PubMed
    1. Sinha MS, Najafzadeh M, Rajasingh EK, Love J, Kesselheim AS. Labeling changes and costs for clinical trials performed under the US Food and Drug Administration pediatric exclusivity extension, 2007 to 2012. JAMA Intern Med. 2018;178(11):1458-1466. doi:10.1001/jamainternmed.2018.3933 - DOI - PMC - PubMed
    1. Grabowski H, Long G, Mortimer R, Bilginsoy M. Continuing trends in U.S. brand-name and generic drug competition. J Med Econ. 2021;24(1):908-917. doi:10.1080/13696998.2021.1952795 - DOI - PubMed